Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Manufacturer Fines Outlined In Rule, But HRSA Expects To Use Them ‘Very Rarely’

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.

You may also be interested in...

340B Pricing, Penalty Alternatives Will Be Reassessed; Final Rule Delayed

Pharma pushback pays off as HRSA requests additional public comment on key issues, including 340B ceiling prices and manufacturer civil monetary penalties.

Manufacturers Say 340B Penalties Proposal Could Punish Actions Outside Their Control

HRSA's proposed rule on civil monetary penalties conflicts with statute's requirement that penalties be imposed only for knowing and intentional program violations, trade groups say.

340B 'Penny Pricing' Policy Draws Manufacturers' Ire

Manufacturers pinpoint flaws in and outline alternatives to HRSA's plan to codify the now non-binding policy of charging a penny per pill for certain products. Concerns are raised about stockpiling and drug diversion, in addition to fair payment.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts